Analysis of anti-HLA antibodies in sensitized kidney transplant candidates subjected to desensitization with intravenous immunoglobulin and rituximab

Transplantation

Volumn 96, Issue 2, 2013, Pages 182-190

  Lobashevsky, Andrew L ^a   Higgins, Nancy G ^a   Rosner, Kevin M ^a   Mujtaba, Muhammad A ^b   Goggins, William C ^b   Taber, Tim E ^b  

^a INDIANA UNIVERSITY HEALTH   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Antibodies; Desensitization; HLA; MFI; Rebound

Indexed keywords

ALLOANTIBODY; HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN G; RITUXIMAB;

ADULT; AGED; ANTIBODY SPECIFICITY; ARTICLE; CLINICAL ARTICLE; DESENSITIZATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HLA TYPING; HUMAN; IMMUNOMODULATION; KIDNEY TRANSPLANTATION; MALE; MONITORING; PRIORITY JOURNAL; REBOUND; SINGLE DRUG DOSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY SPECIFICITY; DESENSITIZATION, IMMUNOLOGIC; FEMALE; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84880570903     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182962c84     Document Type: Article

References (60)

1. Akalin E, Bromberg JS. Intravenous immunoglobulin induction treatment in flow cytometry cross-match-positive kidney transplant recipients. Hum Immunol 2005; 66: 359.
2. Brodin-Sartorius A, Sberro-Soussan R, Suberbielle C, et al. Is an ''acceptable mismatch program'' any better than post-transplant desensitization in donor-specific HLA antibodies plus kidney transplant recipients? Am J Transplant 2012; 12: 525.
3. Gebel HM, Halloran PF. Making sense of desensitization. Am J Transplant 2010; 10: 443.
4. Glotz D, Antoine C, Haymann JP, et al. Intravenous immunoglobulins and kidney transplantation in patients with anti-HLA antibodies. Adv Nephrol Necker Hosp 2000; 30: 221.
5. Jordan SC, Vo AA, Peng A, et al. Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 2006; 6: 459.
6. Jordan SC, Reinsmoen N, Lai CH, et al. Desensitizing the broadly human leukocyte antigen-sensitized patient awaiting deceased donor kidney transplantation. Transplant Proc 2012; 44: 60.
7. Lobashevsky AL, Manwaring JE, Travis MM, et al. Effect of desensitization in solid organ transplant recipients depends on some cytokines genes polymorphism. Transpl Immunol 2009; 21: 169.
8. Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9: 201.
9. Vo AA, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89: 1095.
10. Zachary AA,Montgomery RA, Leffell MS. Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin. Hum Immunol 2005; 66: 364.
11. Blair AR, Smith CI, Reece L, et al. Report from a kidney paired donation centralized lab representing over 70 transplant programs and performing 325 cross matches resulting in 30 transplants. Am J Transplant 2009; 9: 223.
12. Rees MA, Bargnesi D, Samy K, et al. Altruistic donation through the Alliance for Paired Donation. Clin Transpl 2009; 8: 235.
13. Su?sal C, Opelz G. Impact of HLA matching and HLA antibodies in organ transplantation: a collaborative transplant study view. Methods Mol Biol 2012; 882: 267.
14. Piccotti JR, Chan SY, VanBuskirk AM, et al. Are Th2 helper T lymphocytes beneficial, deleterious, or irrelevant in promoting allograft survival? Transplantation 1997; 63: 619.
15. Locke JE, Zachary AA, Warren DS, et al. Proinflammatory events are associated with significant increases in breadth and strength of HLAspecific antibody. Am J Transplant 2009; 9: 2136.
16. Leffell MS, Montgomery RA, Simpkins C, et al. Differences in the response to treatment of antibodies by HLA class specificity. Hum Immunol 2004; 65: S4.
17. Jordan SC, Toyoda M, Vo AA. Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation. Expert Rev Clin Immunol 2011; 7: 341.
18. Fuller A, Profaizer T, Roberts L, et al. Repeat donor HLA-DR mismatches in renal transplantation: is the increased failure rate caused by noncytotoxic HLA-DR alloantibodies? Transplantation 1999; 68: 589.
19. Fairchild RL, VanBuskirk AM, Kondo T, et al. Expression of chemokine genes during rejection and long-term acceptance of cardiac allografts. Transplantation 1997; 63: 1807.
20. Eng HS, Kaplan I, Leffell MS, et al. Variable immunogenicity of HLA antigens. Am J Transplant 2011; 11: 293.
21. Duquesnoy RJ, Marrari M, Mostecki J, et al. Human monoclonal antibody reactivity with HLA class I epitopes defined by eplet pairs. Hum Immunol 2010; 71: S77.
22. Bo?hming GA, Bartel G, Wahrmann M. Antibodies, isotypes and complement in allograft rejection. Curr Opin Organ Transplant 2008; 13: 411.
23. Clatworthy MR. Targeting B cells and antibody in transplantation. Am J Transplant 2011; 11: 1359.
24. Snanoudj R, Candon S, Legendre C. Targeting B cells in sensitized kidney transplant patients: state of the art and future perspectives. Curr Opin Organ Transplant 2010; 15: 709.
25. Ferrari-Lacraz S, Aubert V, Buhler L, et al. Anti-HLA antibody repertoire after IVIg infusion in highly sensitized patients waiting for kidney transplantation. Swiss Med Wkly 2006; 136: 696.
26. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15: 3256.
27. Jordan SC, Vo A, Tyan D, et al. Desensitization therapy with intravenous gammaglobulin (IVIG): applications in solid organ transplantation. Trans Am Clin Climatol Assoc 2006; 117: 199.
28. Marfo K, Ling M, Bao Y, et al. Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients. Transplantation 2012; 94: 345.
29. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLAincompatible kidney recipients and survival.NEngl JMed 2011; 365: 318.
30. Morath C, Zeier M, Su?sal C. Desensitization of HLA-incompatible kidney recipients. N Engl J Med 2011; 365: 1644.
31. Su?sal C, Morath C. Current approaches to the management of highly sensitized kidney transplant patients. Tissue Antigens 2011; 77: 177.
32. Zachary AA, Montgomery RA, Ratner LE, et al. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation 2003; 76: 1519.
33. Haririan A, Nogueira J, Kukuruga D, et al. Positive cross-match living donor kidney transplantation: longer-term outcomes. Am J Transplant 2009; 9: 536.
34. Gloor JM, DeGoey S, Ploeger N, et al. Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation. Transplantation 2004; 78: 221.
35. Marfo K, Lu A, Ling M, et al. Desensitization protocols and their outcome. Clin J Am Soc Nephrol 2011; 6: 922.
36. Caro-Oleas JL, Gonzàlez-Roncero FM, et al. Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation. Nephr Dialysis Transplant 2012; 27: 1231.
37. Leffell MS, Zachary AA. Anti-allograft antibodies: some are harmful, some can be overcome, and some may be beneficial. Discov Med 2010; 9: 478.
38. Leffell MS, Zachary AA. Antiallograft antibodies: relevance, detection, and monitoring. Curr Opin Organ Transplant 2010; 15: 2.
39. Song EY, Lee YJ,Hyun J, et al. Clinical relevance of pretransplant HLAclass II donor-specific antibodies in renal transplantation patients with negative T-cell cytotoxicity crossmatches. Ann Lab Med 2012; 32: 139.
40. Su?sal C, Mahmoud K, Ovens J, et al. Are additional antibodies detected by Luminex single antigen testing clinically relevant? A Collaborative Transplant Study report. Transpl Int 2010; 23: 36.
41. Vittoraki AG, Apostolaki MD, Kontou EN, et al. Frequency of HLADP and MICA antibodies in hyperimmunized renal transplant candidates. Tissue Antigens 2009; 73: 416.
42. Bo?hmig GA, Wahrmann M, Bartel G. Transplantation of the broadly sensitized patient: what are the options? Curr Opin Organ Transplant 2011; 16: 588.
43. Claas FH, Doxiadis II. Management of the highly sensitized patient. Curr Opin Immunol 2009; 21: 569.
44. Morath C, Beimler J, Ovens J, et al. A new approach for the transplantation of sensitized kidney graft recipients at a high risk of antibody-mediated graft loss. Transpl Int 2009; 22: 177.
45. Morath C, Opelz G, Zeier M, et al. Kidney transplantation for highrisk sensitized patientsVthe ''Heidelberg algorithm.'' Transplant Proc 2011; 43: 801.
46. Morath C, Schmidt J, Opelz G, et al. Kidney transplantation in highly sensitized patients: are there options to overcome a positive crossmatch? Langenbecks Arch Surg 2011; 396: 467.
47. Morath C, Beimler J, Opelz G, et al. Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. Transpl Int 2012; 25: 506.
48. Sberro-Soussan R, Zuber J, Suberbielle-Boissel C, et al. Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant 2010; 10: 681.
49. Reinsmoen NL, Lai CH, Vo A, et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 2008; 86: 820.
50. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242.
51. Kozlowski T, Andreoni K. Limitations of rituximab/IVIg desensitization protocol in kidney transplantation; is this better than a tincture of time? Ann Transplant 2011; 16: 19.
52. RogersNM, EngHS, Yu R, et al.Desensitization for renal transplantation: depletion of donor-specific anti-HLA antibodies, preservation of memory antibodies, and clinical risks. Transpl Int 2011; 24: 21.
53. Gu?nther OP, Balshaw RF, Scherer A, et al. Functional genomic analysis of peripheral blood during early acute renal allograft rejection. Transplantation 2009; 88: 942.
54. Gu?nther OP, Lin D, Balshaw RF, et al. Effects of sample timing and treatment on gene expression in early acute renal allograft rejection. Transplantation 2011; 91: 323.
55. Newell KA, Asare A, Kirk AD, et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 2010; 120: 1836.
56. Hamza N, Bos NA, Kallenberg CG. B-cell populations and subpopulations in Sjo?gren's syndrome. Presse Med 2012; 41: e475.
57. Thibault-Espitia A, Foucher Y, Danger R, et al. BAFF and BAFF-R levels are associated with risk of long-term kidney graft dysfunction and development of donor-specific antibodies. Am J Transplant 2012; 12: 2754.
58. Zarkhin V, Li L, Sarwal MM. BAFF may modulate the rate of B-cell repopulation after rituximab therapy for acute renal transplant rejection. Transplantation 2009; 88: 1229.
59. Kamburova EG, Koenen HJ, Boon L, et al. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant 2012; 12: 341.
60. Lobashevsky AL, Higgins NG. Predictive values of class I and class II antibodies detected by Luminex. Hum Immunol 2009: s32.